299 related articles for article (PubMed ID: 28161707)
1. Pathogenesis of Double-Dose Proton Pump Inhibitor-Resistant Non-Erosive Reflux Disease, and Mechanism of Reflux Symptoms and Gastric Acid Secretion-Suppressive Effect in the Presence or Absence of Helicobacter pylori Infection.
Kawami N; Takenouchi N; Umezawa M; Hoshino S; Hanada Y; Hoshikawa Y; Sano H; Hoshihara Y; Nomura T; Uchida E; Iwakiri K
Digestion; 2017; 95(2):140-145. PubMed ID: 28161707
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of Potassium-Competitive Acid Blocker-Resistant Non-Erosive Reflux Disease.
Kawami N; Hoshino S; Hoshikawa Y; Takenouchi N; Umezawa M; Hanada Y; Kaise M; Iwakiri K
Digestion; 2018; 98(3):194-200. PubMed ID: 29870976
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of proton pump inhibitor-resistant nonerosive reflux disease by esophageal manometry and 24-hour esophageal impedance and pH monitoring.
Kawamura O; Hosaka H; Shimoyama Y; Kawada A; Kuribayashi S; Kusano M; Yamada M
Digestion; 2015; 91(1):19-25. PubMed ID: 25632912
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis of proton-pump inhibitor-refractory non-erosive reflux disease according to multichannel intraluminal impedance-pH monitoring.
Kohata Y; Fujiwara Y; Machida H; Okazaki H; Yamagami H; Tanigawa T; Watanabe K; Watanabe T; Tominaga K; Arakawa T
J Gastroenterol Hepatol; 2012 Apr; 27 Suppl 3():58-62. PubMed ID: 22486873
[TBL] [Abstract][Full Text] [Related]
5. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of baseline impedance in patients with proton pump inhibitor-refractory nonerosive reflux disease.
Kohata Y; Fujiwara Y; Yamagami H; Tanigawa T; Shiba M; Watanabe K; Watanabe T; Tominaga K; Arakawa T
J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 1():36-40. PubMed ID: 25827802
[TBL] [Abstract][Full Text] [Related]
7. Predictors of proton pump inhibitor failure in non-erosive reflux disease: A study with impedance-pH monitoring and high-resolution manometry.
Shi Y; Tan N; Zhang N; Xiong L; Peng S; Lin J; Chen M; Xiao Y
Neurogastroenterol Motil; 2016 May; 28(5):674-9. PubMed ID: 26768192
[TBL] [Abstract][Full Text] [Related]
8. [Pathophysiology and Treatment of PPI-resistant NERD].
Kawami N; Iwakiri K; Sakamoto C
Nihon Rinsho; 2015 Jul; 73(7):1197-201. PubMed ID: 26165080
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
[TBL] [Abstract][Full Text] [Related]
10. Acid and non-acid reflux in Japanese patients with non-erosive reflux disease with persistent reflux symptoms, despite taking a double-dose of proton pump inhibitor: a study using combined pH-impedance monitoring.
Iwakiri K; Kawami N; Sano H; Tanaka Y; Umezawa M; Kotoyori M; Hoshihara Y; Sakamoto C
J Gastroenterol; 2009; 44(7):708-12. PubMed ID: 19434361
[TBL] [Abstract][Full Text] [Related]
11. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
12. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor?
Hemmink GJ; Bredenoord AJ; Weusten BL; Monkelbaan JF; Timmer R; Smout AJ
Am J Gastroenterol; 2008 Oct; 103(10):2446-53. PubMed ID: 18684197
[TBL] [Abstract][Full Text] [Related]
13. Role of Reflux in the Pathogenesis of Eosinophilic Esophagitis: Comprehensive Appraisal With Off- and On PPI Impedance-pH Monitoring.
Frazzoni M; Penagini R; Frazzoni L; de Bortoli N; Mauro A; Tolone S; Bertani H; Marsico M; Marocchi M; Marchi S; Conigliaro R; Savarino E
Am J Gastroenterol; 2019 Oct; 114(10):1606-1613. PubMed ID: 31449157
[TBL] [Abstract][Full Text] [Related]
14. Precise role of acid in non-erosive reflux disease.
Wang C; Hunt RH
Digestion; 2008; 78 Suppl 1():31-41. PubMed ID: 18832838
[TBL] [Abstract][Full Text] [Related]
15. Majority of symptoms in esophageal reflux PPI non-responders are not related to reflux.
Roman S; Keefer L; Imam H; Korrapati P; Mogni B; Eident K; Friesen L; Kahrilas PJ; Martinovich Z; Pandolfino JE
Neurogastroenterol Motil; 2015 Nov; 27(11):1667-74. PubMed ID: 26337396
[TBL] [Abstract][Full Text] [Related]
16. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring.
Mainie I; Tutuian R; Shay S; Vela M; Zhang X; Sifrim D; Castell DO
Gut; 2006 Oct; 55(10):1398-402. PubMed ID: 16556669
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system.
Vasiliadis KV; Viazis N; Vlachogiannakos J; Sgouros SN; Stefanidis G; Archimandritis A; Karamanolis DG
Am J Gastroenterol; 2010 Feb; 105(2):308-13. PubMed ID: 19809412
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of symptomatic reflux episodes in Japanese proton pump inhibitor-refractory non-erosive reflux disease patients.
Nakagawa K; Koike T; Iijima K; Saito M; Kikuchi H; Hatta W; Ara N; Uno K; Asano N; Shimosegawa T
World J Gastroenterol; 2015 Dec; 21(47):13352-9. PubMed ID: 26715820
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of low-dose lansoprazole in the treatment of non-erosive gastrooesophageal reflux disease. Influence of infection by Helicobacter pylori.
Castro Fernández M; García Díaz E; Larraona JL; Rodríguez Hornillo MC; Lamas Rojas E; Núñez Hospital D; Pallarés Querol M
Rev Esp Enferm Dig; 2006 Mar; 98(3):170-9. PubMed ID: 16737416
[TBL] [Abstract][Full Text] [Related]
20. [Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease].
Sohn YH; Lee WS; Park CH; Joo YE; Kim HS; Choi SK; Rew JS; Kim SJ
Korean J Gastroenterol; 2006 Sep; 48(3):162-71. PubMed ID: 17047431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
